More recent figures are available via market reports.
http://www.welichem.com/eczema.php The global market value for eczema treatment products was approximately $2.5 billion in 2005; the market size seems certain to grow as the prevalence of eczema in children has risen significantly over the past few decades and continues to rise. The most commonly used therapeutic treatment for eczema is one of the corticosteroids, but they are not recommended for treatments of longer than 4 weeks duration due to their adverse side effects. Two non-steroid drugs currently in the market for the treatment of eczema are the topical immunosuppressants, Elidel and Protopic. However, both brands have experienced steady decline in sales and the FDA has issued warnings against their long term use. Doctors and parents hesitate to treat children with any topical corticosteroid. These factors demonstrate the large market potential and unmet need for a safe, topical, small molecule eczema treatment.
Corticosteroids? No thanks. If AquaLiv works, it could be a safe life-changer for millions of people.